Two standard treatments for low-risk medulloblastoma, compared for effects on thinking
Original title: Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large, late stage trial that compares two treatments already in use.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial compares two standard treatment plans to see how each affects thinking and memory.
Who this trial is for. This trial is for people newly diagnosed with low-risk medulloblastoma that has not spread. It compares two standard treatment plans, called Head Start 4 and HIT-SKK.
Where it stands. The trial is measuring thinking and memory skills 2.5 years after diagnosis. It has not reported any results yet.
What this means, and what it doesn't
What it could mean: Someone who fits this picture could ask their care team about it. Over time, work like this may show which plan is easier on thinking.
What it doesn't mean: A trial is a test, not proven care. Taking part is not a promise that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.